Genflow Biosciences Share Discussion Threads

[northeast14] 08/2/2024 21:49

Money,
Lilly at it again. And then Genf posting about it… more crumbs from Eric

[moneymunch] 08/2/2024 16:57

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,475 followers
4h

We here at Genflow Biosciences (LON:GENF) (OTCQB:GENFF) are proud of the accomplishments we’ve made in 2023 and look forward to an even more prosperous 2024.

We’d like to share our Year-End Review with you, as well as what we are most excited for in the upcoming year:

#healthspan #longevity

[moneymunch] 08/2/2024 16:54

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,475 followers
4h

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) was thrilled to hear that Ely Lilly was successful achieving pharmacologic restoration of hearing in a boy with profound congenital hearing loss. This story highlights joint importance of academic innovation, entrepreneurship, early stage venture capital and large #pharma acquisitions and investment

Read more about the exciting development here:

#longevity #healthspan #biosciences

[moneymunch] 07/2/2024 21:15

R&D results expected imminently from University of Rochester , and no doubt Genflow’s other 3 collaborators conducting in-vivo studies on Genflow’s AAV delivery system for Sirt6, positive results according to Vera will be "powerful" for Sirt6 to translate to human clinical trials, which in turn could be the catalyst for some major interest and major investment imho...Gla :-)

A must listen!!!

[northeast14] 07/2/2024 20:56

I’m sure the likes of Altos, Pfizer, Lilly ect have already showed interest in Genflow. It’s a no Brainer for them. Novo bought out Ventus for $703m in 2022 for there NASH pipeline. These big companies will be all over Genflow. Sit back relax and have the popcorn at the ready
GLA

[luckyabbeygale] 07/2/2024 09:54

I am actually buzzing for an investment to give me the discipline I need for me to keep them long term. There is no better incentive than longevity. That is my purpose of why I want to make money in life. There is not much else I need it for. Usually I say I will be long term and then some other share comes up, and I end up regretting it big time. I have lost out on over a million because of that.

[moneymunch] 07/2/2024 09:23

Those who have sold their shares cheaply in favour of stocks they've recently highlighted here, probably wish they hadn't judging by their performance today, the grass isn't always greener...Gla holders...hold tight for a re-rate or two...more positive newsflow expected soon. :-)

[northeast14] 07/2/2024 07:54

Pie chart, yes totally agree with what you’re saying. I just get very frustrated by the company being so undervalued. Truly value I’m sure will be seen soon hopefully

[northeast14] 07/2/2024 07:52

Lucky, I think you will be ok. You have been adding for a few weeks now. Honestly never thought I’d see the day this was back at these levels. Sadly I can’t top up just now but with 1% of the company I think il do extremely well here

[luckyabbeygale] 07/2/2024 07:44

In the interview it has a cost of £15,000 a year for the treatment if you want to avoid all age illnesses such as cancer etc. I will be adding to my holding in fear of not being able to afford longevity treatment. If your not a shareholder then welcome to all them horrible things that are going to kill you off early.

[pie chart] 07/2/2024 07:33

I've never been less concerned about a share price being so low in all my years of trading. This is an opportunity to get in at what is or is close to the rock bottom this will ever be. Patience and education is the key here. If you have both of those elements down, you will be very wealthy in the not to distant future.

[moneymunch] 07/2/2024 07:26

No doubt plenty will be buying when Vera & Co publish their invivo studies if they confirm positive indications on Sirt6 and Genflow's AAV gene delivery system, which are expected soon. The distressed sellers(s) and the pi's inlfuenced to part with their shares cheaply can only sell their shares once, and so shouldn't be to long before this re-rates to fair value, especially as positive newsflow arrives....Hold tight and enjoy the ride....Genflow will prevail!!! ;-)

[northeast14] 06/2/2024 22:22

We need the Americans buying asap

[moneymunch] 06/2/2024 08:59

A compelling, insightful and exciting podcast on Sirt6's strong and promising potential and influence in longevity and multiple disease targets, with study results expected soon. Gla :-)

[moneymunch] 06/2/2024 08:10

Podcast interview with Vera Gorbunova from 24/10/23 discussing the promising potential for Sirt6 and how she is conducting research in collaboration with Biotech companies, and confirms results should be available in a few months. Gla :-)

SIRT6 The Science Behind The Longevity Gene | Professor Vera Gorbunova Ep1

Oct. 24, 2023

[moneymunch] 06/2/2024 07:24

Accelerator Phase

Accelerator Awards are worth $185,000 to $1 million USD or more and are open to global Catalyst Award winners and finalists. These awards are intended for innovators who have demonstrated significant progress on their early-stage idea or project, preferably achieving proof of concept. Accelerator Award competitions are administered by sponsor organizations, each of which determines its respective eligibility criteria and selection process. Current Accelerator sponsors include Johnson and Johnson Innovation, Eisai Co., Ltd, the European Investment Bank, in partnership with kENUP Foundation, and Primetime Partners.

The Accelerator Phase began in 2021 and will continue through 2025.

Grand Prize Phase

The Grand Prize will serve as the capstone of the competition by rewarding the achievement of a bold and transformative innovation that extends the human healthspan. One or more grand prize(s) of up to $5 million USD will be awarded by the NAM.

The NAM expects to issue the Grand Prize in 2026.

[northeast14] 05/2/2024 17:48

Money, yes I got confirmation that it’s from last year. Second part should be in play now! And fingers crossed he goes all the way to $5m!!

[moneymunch] 05/2/2024 17:44

Hi Northeast, have you a link for the catalyst award, or is it the following one awarded September 2023 in collaboration with Magnaetus Therapeutics which Eric has kept quiet on??? I've been searching for the next phase of the challenge/awards, expected soon , whereby up to £1m plus will be awarded to those $50k catalyst award winners which make it through to the next phase as the most promising??? Gl :-)



September 2023

Developing therapeutic agents reverse ageing and metabolic decline

Cary Depel; Paul Baldock; Guy Barry |

Magnaetus Therapeutics; Eric Leire, MD | Genflow Biosciences

Competition Sponsor: US National Academy of Medicine

Awardee Year: 2023



Magnaetus Therapeutics believes that in order for longevity measures to be most effective, lifespan increases must be twinned with supportive metabolic interventions. This will ensure the ultimate aim of greater quality, as well as quantity of life, for the increasing majority of our population that is overweight/obese.

To deliver on this aim, Magnaetus is working with Genflow Biosciences to develop peptide therapeutics based upon the multiple metabolic activities of a novel circulating protein. Serum levels of this hormone are increased by exercise and calorie restriction, and suppressed by ageing, obesity and inactivity. It exhibits endocrine effects across numerous aspects of the energy economy, acting to mimic the downstream benefits of exercise and calorie restriction.

Longevity is directly targeted through a feed-forward loop with mTOR suppression. This is coupled with additional capabilities, including appetite suppression, fat burning and insulin production/sensitivity. The discrimination of these activities is realised through selection of individual loops of the parent protein’s repeated helical structure, enabling tailoring of therapeutic response to patient needs through production of specific peptide therapeutics.

[steg] 05/2/2024 17:08

Great posts and the upside 👍👍👍

[northeast14] 05/2/2024 15:44

Pie chart great find!

Just let that sink in.

Dr Leire added: “Our treatments are preventative, rather than a cure. We would look to start treating people in their 50s, as age-related diseases tend to start in the 60s.

“It’s envisaged our products would be off the shelf, and patient-friendly, topically administered to the skin or injected via IV. Treatment wouldn’t need to be regular, perhaps every one or two years, at a cost of perhaps £10-£15,000.

1.6p to buy!! Incredible upside here

[pie chart] 05/2/2024 15:32

hxxps://www.biosciencetoday.co.uk/biotech-pioneer-tackles-the-biology-of-ageing/

[northeast14] 05/2/2024 15:26

Eric has been awarded the below

Catalyst Award
Eric Leire
For there bold, new and innovative idea supporting the aims of NAM Healthy Longevity Global Competition to extend health and function as people age

[moneymunch] 04/2/2024 10:15

GenFlow Biosciences partnership with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants 🧬



View organization page for Revatis
Revatis

659 followers
1mo

An excellent start to 2024: our intellectual property is strengthened by the granting of a patent in South Korea, very useful for our tissue engineering projects. #tissueengineering #stemcells #regenerativemedicine #celltherapy #cellandgenetherapy


Updates

View organization page for Revatis
Revatis

659 followers
16h

In Australia, too, our intellectual property rights have been strengthened by the granting of this new patent covering new uses for our technology.




EXO Biologics

2,052 followers
3d

📢 Press Release: ExoXpert Launched by EXO Biologics to Meet Global Exosome Demand.

We are thrilled to announce the worldwide launch of ExoXpert, a cutting-edge contract development and manufacturing organization (CDMO) by EXO Biologics . ExoXpert, with the ExoPulse, platform is dedicated to addressing the increasing demand for exosomes in the biopharmaceutical industry.

"Our vision for ExoXpert is to provide specialized exosome manufacturing capabilities to meet the increasing needs of the market," stated Romain du Hecquet de Rauville, Chief Business Officer at EXO Biologics. "With the launch of ExoXpert, we aim to make a significant contribution to the advancement of exosome-based therapies."

🌐 ExoXpert's Key Features:
🚀 The ExoPulseTM manufacturing platform, designed by EXO Biologics and used in clinical trial, to provide clients a fast-track access to clinic.
🚀 R&D exosome vials on demand
🚀 State-of-the-art exosome manufacturing plant with Grade A/B and C clean rooms.
🚀 Specialized staff and management committed to quality and innovation.


"I'm proud to witness ExoXpert's launch," said Hugues Wallemacq, CEO of EXO Biologics. "This initiative not only tackles the hurdles in exosome production and characterization but also propels the advancement of exosome-based therapeutics on a global scale."



Link to Full Press Release:

[gah123] 03/2/2024 20:22

I've had a few big wins recently, patience always pays with solid plays.

[marmiesz] 03/2/2024 10:12

genf is already conducting in-vivo evaluations of its leading centenarian sirt6 gene therapy in four different nash mice models in conjunction with four leading partners in the field, This to look forward to as the data was collected at the end of 2023. So near term results should be out in the relatively short term. All imo, of course,Marmie